India has quietly turned ancient plant wisdom into one of its fastest-growing manufacturing stories. Ayurveda, once confined to family recipes and village vaids, now runs on GMP-certified lines, export documentation, and organised retail. For anyone scouting business ideas in 2026, herbal and Ayurvedic products manufacturing sits at a rare crossroads of tradition and demand.
This is not a passing wellness fad. Consumers across India and abroad are shifting steadily toward plant-based medicine, skincare, and supplements. That shift is filling factory order books from Haridwar to Kerala. A new entrepreneur today can enter at almost any point in the chain: growing medicinal herbs, extracting active ingredients, formulating finished medicines, or building an export-ready cosmetics brand. Few manufacturing sectors offer this many entry points with government backing attached.
Demand for herbal and Ayurvedic goods is rising on both the domestic and export side at once, which is unusual. Indian households are buying more immunity products, herbal skincare, and plant-based supplements every year. Meanwhile, overseas buyers in the US, Germany, and the Gulf are placing bigger repeat orders. This dual pull gives new manufacturers two separate revenue paths to build around, rather than betting everything on one market.
Timing also favours new entrants. GMP certification is now a realistic goal for a mid-sized plant, not just large corporates. Contract manufacturing has opened doors for brands that want to sell without owning a factory on day one. And raw material supply, long a bottleneck, is improving as government-backed medicinal plant cultivation expands under cluster schemes.
|
Two-thirds of India's herbal export basket still consists of raw herbs and extracts, not finished, branded formulations. (Ministry of AYUSH scheme documentation) |
That imbalance is exactly where new manufacturing capacity can capture far more value than farmers or raw material traders currently do. Profitability follows a similar logic: finished Ayurvedic medicines and herbal cosmetics carry far thicker margins than raw herb trading, especially when sold under a registered brand through e-commerce or export channels rather than as commodity bulk supply.
India's domestic Ayurvedic and herbal products market is already substantial and still climbing. One widely cited industry report pegs it at around Rs. 74,850 crore in 2023, projected to cross Rs. 3.2 lakh crore by 2032 at a compound annual growth rate near 17.5% (industry research estimate). Other analysts place India's 2026 ayurvedic product sales closer to USD 7 billion, growing near 16% a year.
Healthcare products such as immunity boosters, digestive aids, and chronic-care supplements make up the largest single demand block, commonly estimated near 58-60% of category revenue. Personal care, meaning herbal hair oils, skin creams, and oral care, forms the fastest-scaling segment thanks to clean-label and organic positioning.
End users span far beyond individual households. Hospitals and Ayush wellness centres buy formulations in bulk. Hotel and spa chains use herbal oils and cosmetics for treatments. Pharmaceutical and nutraceutical brands buy standardised herbal extracts as raw input, while exporters buy dried herbs, essential oils, and semi-processed extracts for onward sale abroad. Each buyer group needs different volume and certification levels, which is exactly why the sector supports so many differently sized manufacturers at once.
Central government support for this sector is unusually deep and specific, which matters for anyone planning business ideas that need real financial backing. The Ministry of AYUSH runs the National AYUSH Mission, whose Medicinal Plants component offers cultivation subsidies of 30%, 50%, or 75% of cost, depending on the species, across 140 prioritised medicinal plants (Ministry of AYUSH scheme guidelines). The National Medicinal Plants Board also runs the e-CHARAK portal, giving farmers and processors fortnightly price data from 25 herbal markets nationwide.
For manufacturing itself, the Prime Minister's Employment Generation Programme offers a 15-35% capital subsidy on projects up to Rs. 50 lakh through KVIC and state DIC offices, useful for first-time small manufacturers of herbal cosmetics or tablets. CGTMSE-backed collateral-free loans help MSMEs scale working capital without pledging property. On the export side, RoDTEP refunds embedded duties and taxes on shipped goods, while APEDA and Pharmexcil jointly support AYUSH exporters with documentation, trade fair access, and market linkage in Europe and the Gulf.
At the state level, Uttarakhand and Himachal Pradesh run dedicated herbal and medicinal plant board incentives given their Himalayan biodiversity, while Rajasthan and Gujarat offer capital subsidy and SGST reimbursement schemes for MSME manufacturing units under their respective industrial policies. Entrepreneurs should always confirm current scheme terms with the relevant state industries department, since subsidy percentages and caps are periodically revised.
|
A quick word from the consultant's chair: Ayurvedic medicine manufacturing needs a drug licence and stricter GMP compliance, while herbal cosmetics fall under the lighter Cosmetics Rules. Many first-time entrepreneurs underestimate this gap, and it genuinely changes your project cost, timeline, and choice of state. |
Growth in this sector is being pulled by several forces working together rather than any single trend. Rising chronic disease burden is pushing consumers toward preventive, plant-based health routines. Urban India's shift to clean-label personal care is doing the same for cosmetics. Meanwhile, wellness tourism, valued near Rs. 1.64 lakh crore in 2024 and still expanding, creates a steady institutional buyer base for herbal spa and therapy products (Ministry of Commerce data).
Globally, the Ayurveda and herbal products market is estimated near USD 24 billion in 2026, with several independent forecasts placing it between USD 85 billion and USD 124 billion by the mid-2030s, implying a CAGR broadly in the 18-20% range (industry estimates; figures vary by research house). India's own AYUSH manufacturing base grew from roughly USD 18 billion in 2020 to about USD 24 billion by 2024 (IBEF data), confirming that domestic capacity is expanding in step with demand rather than lagging behind it.
|
Year |
Estimated Market Size (Rs. Crore) |
Status |
|
2021 |
58,000 (approx.) |
Historical estimate |
|
2022 |
64,000 (approx.) |
Historical estimate |
|
2023 |
74,850 |
Historical (industry report) |
|
2024 |
88,000 (approx.) |
Historical estimate |
|
2025 |
1,03,000 (approx.) |
Historical estimate |
|
2028 |
1,68,000 (approx.) |
Forecast (assumed 17.5% CAGR) |
|
2030 |
2,32,000 (approx.) |
Forecast (assumed 17.5% CAGR) |
|
2032 |
3,20,760 |
Forecast (industry report) |
|
2035 |
5,20,000 (approx.) |
Forecast (assumed 17.5% CAGR) |
The table above blends a historical run based on published 2023 and 2032 benchmark figures with a forecast built on an assumed 17.5% CAGR. This is an industry assumption, not a confirmed government figure, and actual outcomes will vary by segment and by year.
By 2035, India's Ayurvedic and herbal products market could realistically cross Rs. 5 lakh crore, assuming the current 16-17.5% CAGR broadly holds. This is a projection built on an assumed growth rate, not a confirmed government figure. Even a more conservative CAGR of 12-13%, closer to some analysts' cautious estimates, would still put the market well above Rs. 3 lakh crore by 2035.
Two things will decide which end of that range plays out. First, how fast India moves from exporting raw herbs to exporting finished, branded formulations, since that shift captures far more value per kilogram shipped. Second, how many mid-sized manufacturers achieve WHO-GMP status, since that certification alone unlocks the US, EU, and Gulf markets that currently absorb most of India's herbal exports.
India's AYUSH and herbal exports rose from about USD 612 million in FY 2021-22 to USD 688.9 million in FY 2024-25, a climb of nearly 6% year-on-year (Ministry of Commerce export data). Provisional figures for April 2025 to February 2026 already show close to USD 581 million shipped, suggesting the full-year run rate is holding steady.
The United States remains India's largest buyer, absorbing close to a third of total AYUSH export value, followed by Germany and Italy, with the UAE and Gulf markets close behind. Looking at the broader medicinal and aromatic plants trade specifically, China and India together dominate global supply.
|
China holds close to 25.65% of world exports of medicinal and aromatic plants, while India holds about 17.25%. (NITI Aayog roadmap data, 2021 figures) |
That gap is also the opportunity. Buyers in developed markets increasingly want standardised, lab-tested, traceable herbal extracts, not loose raw material. Entrepreneurs who invest early in GAP-certified cultivation, proper drying and extraction infrastructure, and export documentation stand to capture margin that currently leaks out through unbranded raw exports.
|
Company |
Notes |
|
Dabur India Ltd. |
Market leader by revenue; diversified herbal healthcare, hair care and digestive products with deep rural and urban reach |
|
Patanjali Ayurved Ltd. |
Fast-growing volume leader built on aggressive pricing and a vast distribution network |
|
Himalaya Wellness Company |
Export-strong, science-led formulations across pharmaceuticals, personal care and wellness since 1930 |
|
Emami Ltd. |
Established FMCG major with a sizeable Ayurvedic and herbal personal care portfolio |
|
Shree Baidyanath Ayurved Bhawan |
One of India's oldest classical Ayurvedic medicine manufacturers, strong in traditional formulations |
|
Vicco Laboratories |
Niche leader in herbal oral care and skincare, known for long-standing legacy brands |
|
Kerala Ayurveda Ltd. |
South India-based, strong in classical Ayurvedic treatment products and practitioner-linked formulations |
|
Charak Pharma Pvt. Ltd. |
Mid-sized manufacturer specialising in clinically-oriented herbal and Ayurvedic pharmaceutical products |
These established names do not crowd out new entrants. Most built their scale over decades and now leave real space in regional, niche, and private-label segments, where smaller manufacturers can compete on specialisation rather than sheer size.
Several structural tailwinds support long-term growth here, not just a temporary post-pandemic bump. Government procurement of Ayush medicines for public health programmes is expanding. Insurance and hospital networks are slowly recognising Ayurvedic treatment protocols, widening the addressable healthcare market. Export promotion councils are actively recruiting new registered exporters, and several state industrial policies now list Ayush and herbal manufacturing as priority sectors for capital subsidy.
Consumer behaviour is shifting in the same direction. Younger buyers increasingly prefer plant-based formulations for skincare and wellness, often influenced by social media content around Ayurveda and clean beauty. That demand is not confined to Tier 1 cities. Tier 2 and Tier 3 markets are showing rising per-capita spend on herbal personal care and over-the-counter Ayurvedic remedies, widening the customer base available to smaller regional manufacturers.
|
Unit Type |
Approx. Investment Range |
Notes |
|
Small-scale herbal cosmetics/soap unit |
Rs. 10-15 lakh |
Rented premises, basic machinery, PMEGP-eligible |
|
Ayurvedic tablet/capsule unit (small-medium) |
Rs. 25-50 lakh |
Requires drug licence, tableting/encapsulation machinery |
|
Medium GMP-compliant formulation unit |
Rs. 1-3 crore |
Multiple product lines, dedicated QC lab |
|
WHO-GMP export-oriented plant |
Rs. 5-8 crore |
Needed for US/EU/Gulf export compliance |
|
Medicinal plant cultivation + primary processing |
Rs. 15-40 lakh (per acre-scale unit) |
Eligible for NAM cultivation subsidy of 30-75% |
Costs above are indicative industry estimates and will vary with location, land ownership versus lease, machinery brand, and the exact product basket chosen.
You need a manufacturing licence from the state Ayush drug licensing authority under the Drugs and Cosmetics Act, along with GMP certification for the specific formulations you plan to produce.
Yes, broadly. Herbal cosmetics fall under the Cosmetics Rules rather than the stricter Drug Rules, so licensing and compliance timelines are usually shorter for a first-time entrepreneur.
A small-scale unit producing herbal soaps, tablets, or basic cosmetics can realistically start around Rs. 10-15 lakh, especially if machinery is sourced used or on lease and premises are rented rather than owned.
Yes. Contract manufacturing and job-work arrangements let smaller brands sell finished, exportable products while building their own capacity gradually, provided the contract manufacturer already holds the required certifications.
Uttarakhand and Himachal Pradesh lead on herbal cultivation incentives due to their biodiversity, while Rajasthan and Gujarat offer strong MSME capital subsidy and tax reimbursement schemes for manufacturing units.
Margins vary widely by product and channel, but branded, direct-to-consumer herbal cosmetics commonly earn considerably higher gross margins than raw material trading or unbranded bulk supply.
Herbal and Ayurvedic manufacturing is one of the few Indian industrial sectors where tradition, government policy, and consumer demand are all pulling in the same direction at once. The raw material base is genuinely Indian, the domestic market is large and still growing at double-digit rates, and export markets are actively looking for reliable, certified suppliers.
None of this makes it an easy business. Regulatory pathways differ sharply between cosmetics and medicines, quality control has to be rigorous from day one, and building an export-ready brand takes patience. But for an entrepreneur willing to pick one segment, get the right licence, and build toward GMP or WHO-GMP status, this sector offers a rare combination: real government support, genuine export pull, and a domestic market nowhere near saturated.
1. Ministry of AYUSH, Government of India — National AYUSH Mission Medicinal Plants component and cultivation subsidy structure
2. Press Information Bureau, Government of India — Herbal cultivation package and medicinal plants promotion data
3. India Brand Equity Foundation (IBEF) — AYUSH industry size, exports, and wellness tourism figures
4. NITI Aayog — Strategic Roadmap for Making Ayurveda Global, export growth and country-wise trade share data
5. Grand View Research — Global Ayurveda market size and forecast estimates
6. Federation of Indian Chambers of Commerce and Industry (FICCI) — Herbal and Ayush sector industry outlook commentary
Please choose a project below related to this category.
Moringa leaf powder production is one of the best and most sustainable businesses in the world market. Referred to as the “miracle tree,”...
|
Capacity : 400 Kgs. Per Day |
Plant and Machinery cost: 55 |
|
Working Capital : N/A |
Rate of Return (ROR): 28 |
|
Break Even Point (BEP): 62 |
TCI :
|
|
Cost of Project : 179 |
Herbal extracts are substances extracted from the plant using different solvents—some combination of water, alcohol, chemicals, or other liquid that w...
|
Capacity : - |
Plant and Machinery cost: - |
|
Working Capital : - |
Rate of Return (ROR): 1.00 |
|
Break Even Point (BEP): 0.00 |
TCI : - |
|
Cost of Project : 0 |
In general use, herbs are plants with savory or aromatic properties that are used for flavoring and garnishing food, medicinal purposes, or for fragra...
|
Capacity : - |
Plant and Machinery cost: - |
|
Working Capital : - |
Rate of Return (ROR): 1.00 |
|
Break Even Point (BEP): 0.00 |
TCI : - |
|
Cost of Project : 0 |
Moringa or drum sticks is among the well-known vegetables being used in our food during its availability. It is commonly known as “Sejana”. Drumstick...
|
Capacity : Drumstick (Moringa Oleifere) Powder: 2000 Kgs./day |
Plant and Machinery cost: Rs 38 lakhs |
|
Working Capital : - |
Rate of Return (ROR): 31.00 |
|
Break Even Point (BEP): 72.00 |
TCI : Cost of Project: Rs 92 lakhs |
|
Cost of Project : 9200000 |
Ajwain (Carom Seeds) Ajwain's small, oval-shaped, seed-like fruits are pale brown schizocarps, which resemble the seeds of other plants in the Apiace...
|
Capacity : - |
Plant and Machinery cost: - |
|
Working Capital : - |
Rate of Return (ROR): 1.00 |
|
Break Even Point (BEP): 0.00 |
TCI : - |
|
Cost of Project : 0 |
Calcium sennosides are purified, naturally-occurring derivatives that are extracted from Senna fruits. The active ingredient, sennoside A?B, improve c...
|
Capacity : - |
Plant and Machinery cost: - |
|
Working Capital : - |
Rate of Return (ROR): 1.00 |
|
Break Even Point (BEP): 0.00 |
TCI : - |
|
Cost of Project : 0 |
Safed musli is used for the production of hormone which is very imperative called testosterone it is also used for the effective execution of adrenal...
|
Capacity : - |
Plant and Machinery cost: - |
|
Working Capital : - |
Rate of Return (ROR): 1.00 |
|
Break Even Point (BEP): 0.00 |
TCI : - |
|
Cost of Project : 0 |
Herbal Products Manufacturing Industry. Production of Amla, Triphala, Tooth Powder, Herbal Pellet (Tablet) and Herbal Oil (Hair Oil and Skin Oil). Her...
|
Capacity : - |
Plant and Machinery cost: - |
|
Working Capital : - |
Rate of Return (ROR): 1.00 |
|
Break Even Point (BEP): 0.00 |
TCI : - |
|
Cost of Project : 0 |
Herbal products are medicines derived from plants. They are used as supplements to improve health and wellbeing, and may be used for other therapeutic...
|
Capacity : Amla Powder (200 gms Per Pack): 1000 Packs/Day Triphala Powder (200 gms Per Pack): 1000 Packs/Day Tooth Powder (50 gms Per Pack): 4000 Packs/Day Tablets (50 NosPer Pack): 2000Packs/Day Hair Oil (200 ml Per Pack): 500 Packs/Day Skin Oil (20 |
Plant and Machinery cost: Rs.28 lakhs |
|
Working Capital : - |
Rate of Return (ROR): 31.00 |
|
Break Even Point (BEP): 56.00 |
TCI : Cost of Project: Rs.295 lakhs |
|
Cost of Project : 29500000 |
Aloe Vera Gel and Powder Manufacturing Business. Start a Profitable Aloe Vera Processing Industry Aloe Vera is widely used for its healing and rest...
|
Capacity : - |
Plant and Machinery cost: - |
|
Working Capital : - |
Rate of Return (ROR): 1.00 |
|
Break Even Point (BEP): 0.00 |
TCI : - |
|
Cost of Project : 0 |
Homeopathy is a type of option drug made in 1796 by Samuel Hahnemann taking into account his regulation of like cures like (similia similibus curentur...
|
Capacity : - |
Plant and Machinery cost: - |
|
Working Capital : - |
Rate of Return (ROR): 1.00 |
|
Break Even Point (BEP): 0.00 |
TCI : - |
|
Cost of Project : 0 |
Production of Herbal Wine Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturi...
|
Capacity : - |
Plant and Machinery cost: - |
|
Working Capital : - |
Rate of Return (ROR): 1.00 |
|
Break Even Point (BEP): 0.00 |
TCI : - |
|
Cost of Project : 0 |